ST. LOUIS, July 17, 2018 (GLOBE NEWSWIRE) — GeneriCo, LLC (GeneriCo), a specialty generic drug company, today announced that it completed a deal transaction with a leading US generic pharmaceutical company for the development and commercialization rights for three GeneriCo generic modified release product formulations. Terms of the transaction were not disclosed. “We are pleased … Continued
ST. LOUIS, May 19, 2017 (GLOBE NEWSWIRE) — GeneriCo, LLC (GeneriCo), a global specialty generic drug company, today announced that the Patent Trial and Appeal Board (“PTAB”) of the U.S. Patent and Trademark Office ruled in favor of its petition for Inter Partes Review (“IPR”) of the Valeant Pharmaceuticals International, Inc. U.S. Patent 8,865,688 (the … Continued
St. Louis, MO, January 26, 2017 – GeneriCo, LLC (“GeneriCo”), a global generic specialty pharmaceutical company, is pleased to announce that George R. Stevenson has joined the Company’s Board of Directors as the new Chairman of the Board. Mr. Stevenson brings deep generic and brand pharmaceutical expertise to the GeneriCo Board and is a seasoned … Continued
(St. Louis, MO) –September 8, 2016, GeneriCo, LLC, a global specialty generic pharmaceutical company, has announced the signing of a collaboration with Zhejiang Hisun Pharmaceutical Co, Ltd, and its affiliate Hisun Pharmaceuticals USA, whereby GeneriCo will be the exclusive sales and marketing partner for a portfolio of generic drugs developed and manufactured by Hisun … Continued
St. Louis, MO June 13, 2016 GeneriCo, LLC (GeneriCo), a global specialty generic drug company, today announced it has received a favorable institution decision for its petition for Inter Partes Review (IPR) of United States Patent No. 8,865,688 (the 688 patent) with the United States Patent and Trademark Office (USPTO). The 688 patent, titled, Compositions … Continued
St. Louis, MO – December 15, 2015 GeneriCo, LLC (GeneriCo) today announced that it has recently filed a petition for Inter Partes Review (IPR) of United States Patent No. 8,865,688 (the 688 patent) with the United States Patent and Trademark Office (USPTO). The 688 patent, titled, Compositions and methods for treatment of bowel diseases with … Continued
St. Louis, MO – August 5, 2015 GeneriCo, LLC, based in St. Louis, MO, announces that it has closed on $1.5M of an anticipated $2.0M Series A funding round. GeneriCo is focused on developing and marketing niche generic pharmaceuticals, particularly those having embedded drug delivery technology. Kinsale Capital Partners, LLC is leading the Series A … Continued
St. Louis, MO – June 1, 2013 GeneriCo is a technology driven pharmaceutical company dedicated to the development of specialty generic drugs. The company is founded by industry veterans with over 100 years of combined experience in the development, manufacturing, and sales/marketing of both branded and generic pharmaceutical products. The founding team has serial successes … Continued
Original posting date – May 22, 2013 – St. Louis, MO St. Louis-based GeneriCo LLC is in the middle of a $2.5 million fundraising round, according to a recent filing with the U.S. Securities and Exchange Commission (SEC). Generico develops and markets generic pharmaceuticals. It focuses on generics that have been neglected by mid and … Continued